PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 123 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $2,356,000 | +36.2% | 272,710 | -0.2% | 0.00% | +50.0% |
| Q3 2016 | $1,730,000 | +57.1% | 273,226 | +4.7% | 0.00% | +100.0% |
| Q2 2016 | $1,101,000 | +2.2% | 260,867 | +5.6% | 0.00% | 0.0% |
| Q1 2016 | $1,077,000 | -28.1% | 247,014 | +1.1% | 0.00% | -50.0% |
| Q4 2015 | $1,497,000 | +7.2% | 244,241 | +0.1% | 0.00% | 0.0% |
| Q3 2015 | $1,396,000 | -24.3% | 244,093 | -1.2% | 0.00% | 0.0% |
| Q2 2015 | $1,843,000 | +37.4% | 246,993 | +10.1% | 0.00% | 0.0% |
| Q1 2015 | $1,341,000 | -20.4% | 224,235 | +0.6% | 0.00% | 0.0% |
| Q4 2014 | $1,685,000 | +43.8% | 222,923 | -1.3% | 0.00% | 0.0% |
| Q3 2014 | $1,172,000 | +22.2% | 225,807 | +1.5% | 0.00% | +100.0% |
| Q2 2014 | $959,000 | +18.2% | 222,550 | +12.2% | 0.00% | 0.0% |
| Q1 2014 | $811,000 | -11.3% | 198,377 | +15.7% | 0.00% | 0.0% |
| Q4 2013 | $914,000 | +4.5% | 171,482 | -1.6% | 0.00% | 0.0% |
| Q3 2013 | $875,000 | +38.4% | 174,224 | +23.0% | 0.00% | 0.0% |
| Q2 2013 | $632,000 | – | 141,601 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |